Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Publication | Open Access

DOI Full Paper Access

1.7K

Citations

References

2020

Year

Javier Cortés, David W. Cescon, Hope S. Rugo, Zbigniew Nowecki, Seock‐Ah Im, Mastura Md Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H. Barrios, Holgado Esther,

The Lancet

Chemotherapy Versus PlaceboBreast OncologyOncologyClinical TrialsBreast CancerPharmacotherapyCancer TreatmentMedicineRadiation OncologyHealth Sciences